143 related articles for article (PubMed ID: 36030026)
1. Pyrroloquinoline quinone (PQQ) improves pulmonary hypertension by regulating mitochondrial and metabolic functions.
Shafiq M; Lone ZR; Bharati P; Mahapatra S; Rai P; Khandelwal N; Gaikwad AN; Jagavelu K; Hanif K
Pulm Pharmacol Ther; 2022 Oct; 76():102156. PubMed ID: 36030026
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial regulation by pyrroloquinoline quinone prevents rotenone-induced neurotoxicity in Parkinson's disease models.
Lu J; Chen S; Shen M; He Q; Zhang Y; Shi Y; Ding F; Zhang Q
Neurosci Lett; 2018 Nov; 687():104-110. PubMed ID: 30240821
[TBL] [Abstract][Full Text] [Related]
3. Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling.
Jin H; Jiao Y; Guo L; Ma Y; Zhao R; Li X; Shen L; Zhou Z; Kim SC; Liu J
Int J Mol Med; 2021 Feb; 47(2):595-606. PubMed ID: 33416126
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle.
Paffett ML; Lucas SN; Campen MJ
Vascul Pharmacol; 2012; 56(1-2):64-73. PubMed ID: 22146233
[TBL] [Abstract][Full Text] [Related]
5. Calcineurin/NFAT Signaling Modulates Pulmonary Artery Smooth Muscle Cell Proliferation, Migration and Apoptosis in Monocrotaline-Induced Pulmonary Arterial Hypertension Rats.
He RL; Wu ZJ; Liu XR; Gui LX; Wang RX; Lin MJ
Cell Physiol Biochem; 2018; 49(1):172-189. PubMed ID: 30134231
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of pyrroloquinoline quinone against rotenone injury in primary cultured midbrain neurons and in a rat model of Parkinson's disease.
Zhang Q; Chen S; Yu S; Qin J; Zhang J; Cheng Q; Ke K; Ding F
Neuropharmacology; 2016 Sep; 108():238-51. PubMed ID: 27108097
[TBL] [Abstract][Full Text] [Related]
7. Docosahexaenoic acid inhibits monocrotaline-induced pulmonary hypertension via attenuating endoplasmic reticulum stress and inflammation.
Chen R; Zhong W; Shao C; Liu P; Wang C; Wang Z; Jiang M; Lu Y; Yan J
Am J Physiol Lung Cell Mol Physiol; 2018 Feb; 314(2):L243-L255. PubMed ID: 29097423
[TBL] [Abstract][Full Text] [Related]
8. Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension.
Abdulkareem AO; Tiwari P; Lone ZR; Iqbal H; Gupta S; Jha RK; Chanda D; Jagavelu K; Hanif K
Eur J Pharmacol; 2023 Mar; 943():175558. PubMed ID: 36731722
[TBL] [Abstract][Full Text] [Related]
9. Pyrroloquinoline quinone ameliorates diabetic cardiomyopathy by inhibiting the pyroptosis signaling pathway in C57BL/6 mice and AC16 cells.
Qu XF; Zhai BZ; Hu WL; Lou MH; Chen YH; Liu YF; Chen JG; Mei S; You ZQ; Liu Z; Zhang LJ; Zhang YH; Wang Y
Eur J Nutr; 2022 Jun; 61(4):1823-1836. PubMed ID: 34997266
[TBL] [Abstract][Full Text] [Related]
10. Pyrroloquinoline Quinone Inhibits Rotenone-Induced Microglia Inflammation by Enhancing Autophagy.
Zhang Q; Zhou J; Shen M; Xu H; Yu S; Cheng Q; Ding F
Molecules; 2020 Sep; 25(19):. PubMed ID: 32977419
[TBL] [Abstract][Full Text] [Related]
11. PRDX6-mediated pulmonary artery endothelial cell ferroptosis contributes to monocrotaline-induced pulmonary hypertension.
Liao J; Xie SS; Deng Y; Wu DD; Meng H; Lan WF; Dai P
Microvasc Res; 2023 Mar; 146():104471. PubMed ID: 36566948
[TBL] [Abstract][Full Text] [Related]
12. N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats.
Chaumais MC; Ranchoux B; Montani D; Dorfmüller P; Tu L; Lecerf F; Raymond N; Guignabert C; Price L; Simonneau G; Cohen-Kaminsky S; Humbert M; Perros F
Respir Res; 2014 Jun; 15(1):65. PubMed ID: 24929652
[TBL] [Abstract][Full Text] [Related]
13. Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats.
Horstman DJ; Frank DU; Rich GF
Anesth Analg; 1998 Jan; 86(1):74-81. PubMed ID: 9428855
[TBL] [Abstract][Full Text] [Related]
14. Eicosapentaenoic acid ameliorates pulmonary hypertension via inhibition of tyrosine kinase Fyn.
Kurahara LH; Hiraishi K; Yamamura A; Zhang Y; Abe K; Yahiro E; Aoki M; Koga K; Yokomise H; Go T; Ishikawa K; Bo Z; Kishi H; Kobayashi S; Aoki-Shoi N; Toru S; Inoue R; Hirano K
J Mol Cell Cardiol; 2020 Nov; 148():50-62. PubMed ID: 32889002
[TBL] [Abstract][Full Text] [Related]
15. Icotinib Attenuates Monocrotaline-Induced Pulmonary Hypertension by Preventing Pulmonary Arterial Smooth Muscle Cell Dysfunction.
Peng LY; Yu M; Yang MX; Liu P; Zhou H; Huang W; Kong H; Xie WP
Am J Hypertens; 2020 Aug; 33(8):775-783. PubMed ID: 32301965
[TBL] [Abstract][Full Text] [Related]
16. Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats.
Tofovic SP; Salah EM; Mady HH; Jackson EK; Melhem MF
J Cardiovasc Pharmacol; 2005 Oct; 46(4):430-7. PubMed ID: 16160593
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib alleviates experimental pulmonary arterial hypertension.
Kim SY; Lee JH; Huh JW; Kim HJ; Park MK; Ro JY; Oh YM; Lee SD; Lee YS
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):698-708. PubMed ID: 22842494
[TBL] [Abstract][Full Text] [Related]
18. Involvement of asymmetric dimethylarginine and Rho kinase in the vascular remodeling in monocrotaline-induced pulmonary hypertension.
Li XH; Peng J; Tan N; Wu WH; Li TT; Shi RZ; Li YJ
Vascul Pharmacol; 2010; 53(5-6):223-9. PubMed ID: 20840872
[TBL] [Abstract][Full Text] [Related]
19. 2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling.
Tofovic SP; Zhang X; Zhu H; Jackson EK; Rafikova O; Petrusevska G
Vascul Pharmacol; 2008; 48(4-6):174-83. PubMed ID: 18373958
[TBL] [Abstract][Full Text] [Related]
20. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
